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keletal muscle growth requires multiple steps to form
large multinucleated muscle cells. Molecules that
stimulate muscle growth may be therapeutic for muscle
loss associated with aging, injury, or disease. However, few
factors are known to increase muscle cell size. We demon-
 
strate that prostaglandin F
 
2
 
 
 
 (PGF
 
2
 
 
 
) as well as two analogues
augment muscle cell size in vitro. This increased myotube
size is not due to PGF
 
2
 
 
 
-enhancing cell fusion that initially
forms myotubes, but rather to PGF
 
2
 
 
 
 recruiting the fusion of
cells with preexisting multinucleated cells. This growth is
mediated through the PGF
 
2
 
 
 
 receptor (FP receptor). As the
FP receptor can increase levels of intracellular calcium, the
S
 
involvement of the calcium-regulated transcription factor
nuclear factor of activated T cells (NFAT) in mediating
PGF
 
2
 
 
 
-enhanced cell growth was examined. We show that
NFAT is activated by PGF
 
2
 
 
 
, and the isoform NFATC2 is
required for PGF
 
2
 
 
 
-induced muscle cell growth and nuclear
accretion, demonstrating the ﬁrst intersection between
prostaglandin receptor activation and NFAT signaling.
Given this novel role for PGF
 
2
 
 
 
 in skeletal muscle cell
growth, these studies raise caution that extended use of
drugs that inhibit PG production, such as nonsteroidal anti-
inﬂammatory drugs, may be deleterious for muscle growth.
 
Introduction
 
Skeletal myogenesis follows an ordered set of cellular events
involving cell cycle exit of myoblasts, their subsequent dif-
ferentiation, and fusion to form multinucleated myofibers in
vivo or myotubes in vitro. In most cases, mammalian muscle
growth requires the fusion of differentiated muscle cells with
the growing multinucleated muscle cell (Darr and Schultz,
1989; Rosenblatt and Parry, 1992; Phelan and Gonyea,
1997; Barton-Davis et al., 1999; Horsley et al., 2001;
Mitchell and Pavlath, 2001). By adding additional nuclei to
muscle cells during growth, an increased number of nuclei
are contained within one cytoplasm, allowing each nucleus
to regulate more cytoplasm (Allen et al., 1999). These fusion
events allow increased protein synthesis and increases in cell
size. Understanding the molecular pathways that regulate
muscle growth are important for treating muscle disorders
and loss of muscle mass during aging. However, few molecules
are known to stimulate increased muscle cell fusion and skeletal
muscle growth.
Prostaglandins (PGs)* are paracrine signaling molecules
that are synthesized from arachidonic acid in response to
cytokines, cell injury, or growth factors (Funk, 2001). The
synthesis of PGs involves the metabolism of arachidonic acid
by cyclooxygenase enzymes into an intermediate PG. Specific
PG synthases convert this intermediate PG into the primary
PG molecules (PGE
 
2
 
, PGF
 
2
 
 
 
, PGI
 
2
 
, and PGD
 
2
 
). Once pro-
duced, PGs are secreted and mediate signaling through G
protein–coupled receptors that are distinct for each PG.
Activation of PG receptors leads to an array of effects in a
range of cell and tissue types, including skeletal muscle.
PGs have been implicated in skeletal muscle growth. For
skeletal muscle to grow, a population of myoblasts must be
available to differentiate and fuse with the myofiber. Different
PGs can control proliferation (Zalin, 1987), differentiation
(Schutzle et al., 1984), as well as fusion of myoblasts (Zalin,
1977; David and Higginbotham, 1981; Entwistle et al.,
1986; Rossi et al., 1989). Once myotubes are formed, muscle
cell size continues to increase through enhanced protein syn-
thesis. PGs regulate this stage of growth by altering both
protein degradation and protein synthesis within myotubes
(Rodemann and Goldberg, 1982; Palmer, 1990; Vandenburgh
et al., 1990). Consistent with a general role for PGs in skeletal
muscle growth, inhibition of PG production blocks growth
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of myofibers in vivo (Templeton et al., 1986; McLennan,
1987). These data suggest that PGs regulate muscle cell
growth by influencing multiple steps of myogenesis.
Signaling pathways that are activated by calcium are im-
portant for skeletal muscle growth (Abbott et al., 1998;
Dunn et al., 1999; Musaro et al., 1999; Semsarian et al.,
1999; Delling et al., 2000; Friday et al., 2000; Horsley et al.,
2001; Mitchell et al., 2002). PGs have been shown to acti-
vate increases in intracellular calcium within a variety of
muscle cell types (Asboth et al., 1996; Chen et al., 1997;
Yew et al., 1998; Yousufzai and Abdel-Latif, 1998). Specifi-
cally, PGF
 
2
 
 
 
 and PGE
 
2
 
 can activate increases in intracellular
calcium through their receptors, PGF
 
2
 
 
 
 receptor (FP) and
EP
 
1
 
/EP
 
3
 
, respectively (Breyer et al., 2001). One calcium-reg-
ulated pathway involved in skeletal muscle growth is the
family of transcription factors, nuclear factor of activated T
cells (NFAT; Horsley and Pavlath, 2002). Several NFAT
isoforms are expressed in skeletal muscle, and the regulation
of individual NFAT isoforms appears to occur at the level of
nuclear translocation (Abbott et al., 1998). For instance, the
NFATC2 isoform is activated only in newly formed or na-
scent myotubes but not at other stages of myogenesis (Ab-
bott et al., 1998). Previously, we have shown that the
NFATC2 isoform is important for skeletal muscle growth
(Horsley et al., 2001), but upstream activators of this path-
way have not been elucidated.
Because PGF
 
2
 
 
 
 can increase intracellular calcium and cal-
cium signaling pathways are important for numerous stages
of myogenesis that contribute to muscle growth, we hypoth-
esized that PGF
 
2
 
 
 
 may regulate skeletal muscle growth. Al-
though PGF
 
2
 
 
 
 can regulate the final stages of muscle growth
by inducing protein synthesis (Vandenburgh et al., 1990),
we sought to investigate the role of PGF
 
2
 
 
 
 in other steps of
myogenesis that require calcium, such as differentiation
(Shainberg et al., 1969; Morris and Cole, 1979) and fusion
(Shainberg et al., 1969; Knudsen and Horwitz, 1977). We
show that PGF
 
2
 
 
 
 enhances myonuclear accretion after the
initial formation of myotubes, leading to increases in myo-
tube size. Furthermore, the growth induced by PGF
 
2
 
 
 
 oc-
curs through an NFAT-dependent pathway. These data im-
plicate not only a novel function for PGF
 
2
 
 
 
 in skeletal
muscle growth but also a novel intersection between pros-
taglandin and NFAT signaling pathways.
 
Results
 
PGF
 
2
 
 
 
 increases muscle cell size and nuclear number
 
To test the hypothesis that PGF
 
2
 
 
 
 has a role in the growth of
skeletal muscle cells, differentiating primary muscle cultures
were treated with different doses of PGF
 
2
 
 
 
 or with a stable
synthetic analogue of PGF
 
2
 
 
 
, 17-phenyl trinor PGF
 
2
 
 
 
 (17-
phPGF
 
2
 
 
 
). After 24 h, the majority of cells are differentiated
and have formed a few multinucleated cells. Although no
difference is apparent between the vehicle- and drug-treated
groups at 24 h, after 48 h, drug-treated myotubes are larger
in size as compared with vehicle (Fig. 1 A), suggesting that
PGF
 
2
 
 
 
 can regulate muscle growth.
The formation of a multinucleated cell requires multiple
cellular processes including the formation of an adequate
number of myoblasts through cell proliferation, their differ-
entiation, and subsequent membrane fusion. To determine
if PGF
 
2
 
 
 
 increases cell proliferation and/or cell survival in
our assay, the DNA content was quantified. No difference
exists in the DNA content between PGF
 
2
 
 
 
 and vehicle-
treated cells (Fig. 1 B). Differentiation was assessed in vehi-
cle and PGF
 
2
 
 
 
-treated cultures at 24 and 48 h by immu-
nostaining the cultures with embryonic myosin heavy chain
(EMyHC), a marker of differentiation, and counting the
number of nuclei contained within EMyHC-positive cells.
The percentage of differentiated cells does not differ be-
Figure 1. PGF2  increases myotube 
size by facilitating muscle cell fusion. 
(A) Primary myoblasts were induced to 
differentiate in the presence of vehicle 
(10
 6 M PGF2  or 10
 7 M 17-phPGF2 ) 
and immunostained for EMyHC at the 
indicated times. Bar, 60  m. (B) The DNA 
content of myotube cultures treated with 
vehicle or 10
 6 M PGF2  was quantified 
after 48 h in DM. (C) The percentage of 
nuclei within EMyHC-positive cells was 
analyzed after treatment with vehicle 
or 10
 6 M PGF2  at the indicated times. 
(D) The percentage of nuclei within 
myotubes was calculated after treatment 
with vehicle or 10
 6 M PGF2  at the 
indicated times. (E) Cells were treated 
with the indicated doses of PGF2  for 
48 h, and the number of nuclei within 
individual myotubes was counted. 
Myotubes were grouped into two 
categories, and the percentage of myotubes in each category was determined. Data are mean   SEM of three independent cell isolates. 
*Significantly different from vehicle, P   0.05. (F) Cells were treated with the indicated doses of 17-phPGF2  for 48 h, and the number of 
nuclei within individual myotubes was counted as in E. Data are mean   SEM of three independent experiments. *Significantly different from 
vehicle, P   0.05. (G) Cells were treated with vehicle or 10
 6 M PGF2  at 0, 24, or both 0 and 24 h. Nuclear number assays were performed 
as in E, and the percentage of myotubes with five or more nuclei is shown. Data are mean   SEM of three independent experiments. *Significantly 
different from vehicle, P   0.05.T
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tween vehicle- or PGF
 
2
 
 
 
-treated cultures at 24 or 48 h (Fig.
1 C). In addition, the fusion index was determined. The
percentage of nuclei in myotubes is not different between
vehicle- or PGF
 
2
 
 
 
-treated cultures (Fig. 1 D). These data
suggest that PGF
 
2
 
 
 
 does not affect myoblast proliferation or
survival, differentiation, or fusion to lead to muscle growth.
After the initial fusion of myoblasts that forms a multinu-
cleated cell, cell growth occurs through the fusion of differ-
entiated muscle cells with the nascent myotube to increase
myonuclear number and cell size (Bate, 1990; Horsley et al.,
2001). Although the fusion index determines the percentage
of the total cell population that has fused within muscle cul-
tures, it is not a measure of the number of myonuclei within
individual myotubes. By analyzing the myonuclear number
within individual myotubes, cell fusion that contributes to
muscle growth can be determined. To determine if PGF
 
2
 
 
 
increases muscle cell size by enhancing addition of myonu-
clei to existing myotubes, the number of nuclei in individual
myotubes was determined in cultures treated with vehicle
and PGF
 
2
 
 
 
 for 48 h. With vehicle treatment, an equal per-
centage of myotubes are present with two to four nuclei as
those with five or more nuclei (Fig. 1 E). However, with
10
 
 
 
6
 
 M PGF
 
2
 
 
 
 treatment, a significant increase occurs in the
percentage of myotubes with five or more nuclei with a par-
allel decrease in the percentage of myotubes with two to four
nuclei. This dose of PGF
 
2
 
 
 
 has been shown to give maximal
effects in assays using cardiac and smooth muscle cells (Ad-
ams et al., 1996; Griffin et al., 1998; Kunapuli et al., 1998;
Yew et al., 1998; Katsuyama et al., 2002). Other doses of
PGF
 
2
 
 
 
 tested do not significantly differ from vehicle. Simi-
larly, treatment of cells with 17-phPGF
 
2
 
 
 
 also increases
myonuclear number to the same extent as PGF
 
2
 
 
 
 but at lower
doses (Fig. 1 F), which is consistent with its higher affinity
and greater metabolic stability (Lake et al., 1994; Pierce et
al., 1997). These data suggest that PGF
 
2
 
 
 
 increases cell fu-
sion with myotubes to facilitate increases in muscle cell size.
To further study the effect of PGF
 
2
 
 
 
 on increases in myo-
nuclear number, differentiating muscle cells were treated
with PGF
 
2
 
 
 
 at different stages of fusion. To determine if
PGF
 
2
 
 
 
 can act at the initial stages of cell fusion, cells were
only treated with PGF
 
2
 
 
 
 at the onset of differentiation at 0 h
in differentiation media (DM). To determine if PGF
 
2
 
 
 
 acts
during later fusion events, cells were only treated at 24 h, a
time when cells are beginning to fuse and a few multinucle-
ated muscle cells are present (Fig. 1 A). In both cases, the nu-
clear number of individual myotubes was analyzed at 48 h, as
in Fig. 1 E. When PGF
 
2
 
 
 
 is administered at the onset of dif-
ferentiation (0 h), no significant difference exists in the per-
centage of myotubes with five or more nuclei as compared
with vehicle-treated cultures (Fig. 1 G). However, when
PGF
 
2
 
 
 
 is administered at 24 h, the percentage of myotubes
with five or more nuclei is significantly higher than vehicle-
treated cells. This difference is comparable to the increase in
nuclear number when PGF
 
2
 
 
 
 is added at both 0 and 24 h.
These data further confirm that PGF
 
2
 
 
 
 acts at later stages of
muscle cell fusion to allow an increase in muscle cell size.
 
Activation of the FP receptor induces cell growth
 
PGF
 
2
 
 
 
 primarily mediates its cellular effects by binding with
high affinity (K
 
i 
 
  
 
3.4 nM) to the FP prostanoid receptor
 
(Breyer et al., 2001). However, PGF
 
2
 
 
 
 can also bind with
lower affinity to EP
 
1
 
 (K
 
i 
 
  
 
1,300 nM) and EP
 
3
 
 (K
 
i 
 
  
 
75
nM) receptors. To determine if muscle growth induced by
the addition of PGF
 
2
 
 
 
 occurs through the FP receptor, cells
were treated with a specific FP agonist (fluprostenol) that
has a similar affinity for the FP receptor as PGF
 
2
 
 
 
 (K
 
i 
 
  
 
3.8
nM) but does not bind to other prostanoid receptors (Breyer
et al., 2001). Fluprostenol induces an increase in muscle cell
size (Fig. 2 A) as well as an increase in myonuclear number
to the same extent as PGF
 
2
 
 
 
 at similar doses (Fig. 2 B).
To determine if endogenous PGF2  regulates myonuclear
accretion and acts through the FP receptor, cells were
treated with a selective, competitive FP antagonist, AL-8810
(Ki   426 nM; Griffin et al., 1998, 1999), after 24 h in
DM corresponding to the later stages of fusion. In the pres-
ence of  10
 7 M AL-8810, myotube cultures contain few
cells with five or more nuclei (Fig. 2 C). Together, these
data suggest that PGF2 -induced muscle growth is mediated
through the FP receptor and that endogenous PGF2  is re-
quired for muscle growth.
NFAT activity is required for muscle growth by PGF2 
PGF2  signaling is known to increase levels of intracellular
calcium in a variety of cell types including smooth muscle
and cardiac muscle (Yew et al., 1998; Yousufzai and Abdel-
Latif, 1998). NFAT is a family of calcium-regulated tran-
scription factors that has been implicated in skeletal muscle
growth (Musaro et al., 1999; Horsley et al., 2001; Kegley et
al., 2001). To investigate whether NFAT is involved in
PGF2 -induced skeletal muscle growth, cells were infected
with a retrovirus encoding VIVIT, a specific peptide inhibi-
tor of NFAT activation. VIVIT acts by preventing the inter-
action between NFAT and calcineurin but not between cal-
cineurin and other substrates (Aramburu et al., 1999; Friday
et al., 2000; Friday and Pavlath, 2001). Primary muscle cells
infected with control retrovirus exhibit an increase in cell
size when treated with 10
 6 M PGF2  (Fig. 3 A), similar to
Figure 2. PGF2 -mediated muscle growth occurs through the FP 
receptor. (A) Primary myoblasts were induced to differentiate in the 
presence of vehicle, 10
 6 M fluprostenol, or 10
 6 M AL-8810 and 
immunostained for EMyHC after 48 h. Bar, 60  m. (B) Cells were 
treated with the indicated doses of fluprostenol for 48 h and analyzed 
as in Fig. 1 E. (C) After 24 h in DM, cells were treated with indicated 
doses of AL-8810 for 24 h and analyzed as in Fig. 1 E. Data are 
mean   SEM of three independent experiments. *Significantly 
different from vehicle, P   0.05.T
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uninfected cells (Fig. 1 A). In contrast, cells infected with
VIVIT retrovirus do not increase cell size when treated with
PGF2 . To quantify these observations, we analyzed the cul-
tures with the nuclear number assay used in Fig. 1. Cells in-
fected with control retrovirus and treated with PGF2  show
a significant increase in the percentage of myotubes with five
or more nuclei. However, cells infected with the VIVIT
retrovirus and treated with PGF2  are similar in nuclear
number to nontreated cells. These data implicate that a
calcineurin- and NFAT-dependent signaling pathway is in-
volved in skeletal muscle growth induced by PGF2 .
PGF2  activates nuclear translocation and 
transcriptional activity of NFAT
Given the requirement of NFAT in PGF2 -induced muscle
growth, direct activation of NFAT signaling by PGF2  was
analyzed in muscle cells. First, cells were transiently trans-
fected with an NFATC2-GFP fusion construct and treated
with 10
 6 M PGF2  after 24 h in DM. Without treatment,
cells expressing NFATC2-GFP exhibit GFP throughout the
cell (Fig. 4 A). Stimulation with PGF2  results in transloca-
tion and accumulation of NFAT in nuclei of myotubes.
This nuclear translocation of NFAT is blocked by treatment
with cyclosporine A (CsA), suggesting that calcineurin is ac-
tivated by PGF2 . In addition, PGF2 -induced nuclear trans-
location of NFATC2 is inhibited by cotreatment with the
FP antagonist, AL-8810. Thus, stimulation of the FP recep-
tor is responsible for NFAT activation and not a nonspecific
increase in intracellular calcium at this dose of PGF2 . Tran-
scriptional activity of NFAT was analyzed also in cells con-
taining a NFAT responsive luciferase reporter construct
(Fig. 5 B). Luciferase activity is increased in cells treated
with 10
 6 M PGF by approximately ninefold. Together,
these data indicate that PGF2  activates NFAT signaling in
skeletal muscle.
PGF2  affects myotube size through NFATC2
Three isoforms of NFAT are expressed in skeletal muscle cells
(Abbott et al., 1998). Because the NFATC2 isoform regulates
skeletal muscle growth (Horsley et al., 2001) and is activated
by PGF2  (Fig. 4), we investigated whether NFATC2 is re-
quired for cell growth induced by PGF2  by examining
NFATC2
 /  muscle cells treated with PGF2 . NFATC2
 / 
cells differentiate and initially fuse normally but have a de-
fect in further myonuclear accretion that prevents muscle
cell growth (Horsley et al., 2001). Addition of PGF2  to
NFATC2
 /  cultures does not increase myotube size (Fig. 5
Figure 3. PGF2  increases myotube size through an NFAT-dependent 
pathway. (A) Primary myoblasts were infected either with control 
retrovirus (Cntl RV) or with a retrovirus expressing VIVIT, a peptide 
inhibitor of NFAT (VIVIT RV). Cells were induced to differentiate 
in the presence of vehicle or 10
 6 M PGF2  for 48 h, and then 
immunostained for EMyHC. Bar, 60  m. (B) Nuclear number assays 
were performed on the retrovirally infected cultures as in Fig. 1 E. 
Data are mean   SEM of three independent experiments. *Significantly 
different from vehicle, P   0.05.
Figure 4. PGF2  activates nuclear 
translocation and transcriptional activity 
of NFAT in muscle cells. (A) After 24 h 
in DM, transiently transfected cells 
expressing an NFATC2-GFP fusion protein 
were treated with 10
 6 M PGF2  alone or 
in combination with 10
 6 M CsA or 
10
 6 M AL-8810. Arrowheads indicate 
the location of nuclei in both GFP and 
Hoescht images. Data are representative 
of three independent experiments. 
Bar, 60  m. (B) Myoblasts were 
transiently transfected with an NFAT-
responsive reporter and after 24 h in DM, 
stimulated with 10
 6 M PGF2  alone or 
in combination with 10
 6 M CsA. Data 
are reported as fold increase in luciferase 
activity over basal. Each bar represents 
the mean   SEM of four independent 
experiments each performed in triplicate. 
*Significantly different from basal and 
PGF2  and CsA, P   0.05.T
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A) or nuclear number (Fig. 5 B) at a range of doses, suggesting
that NFATC2 is required for PGF2 -induced growth.
The inability of NFATC2
 /  muscle cells to grow in re-
sponse to PGF2  may result from reduced expression of the
FP receptor in these mutant cells. To determine if NFATC2
regulates the expression of the FP receptor, mRNA levels of
the FP receptor were examined in wild-type and NFATC2
 / 
cells using RT-PCR. As shown in Fig. 5 C, the FP receptor
is expressed in both wild-type and NFATC2
 /  cells. Thus,
NFATC2 is not necessary for the expression of the FP recep-
tor but rather functions downstream of FP receptor activa-
tion in skeletal muscle cells.
To further test whether PGF2  requires NFATC2 to in-
duce muscle growth, we determined if expression of a re-
combinant NFATC2 in NFATC2
 /  muscle cells could res-
cue the inability of these cells to increase in cell size and
nuclear number in response to PGF2 . When treated with
10
 6 M PGF2 , NFATC2
 /  muscle cells infected with con-
trol retrovirus do not increase in size (Fig. 6 A) or in the per-
centage of myotubes with five or more nuclei (Fig. 6 B).
Consistent with previous results (Horsley et al., 2001), ex-
pression of a recombinant NFATC2 in NFATC2
 /  muscle
cells restores myotube growth. However, NFATC2
 /  cells
expressing a recombinant NFATC2 and treated with PGF2 
exhibit a greatly enhanced cell size relative to similarly treated
wild-type cells that is associated with an increase in nuclear
number. These data further demonstrate that PGF2 -induced
muscle growth is mediated through NFATC2-dependent
pathways.
Discussion 
The majority of molecules known to regulate muscle cell fu-
sion in mammals mediate the initial formation of a multinu-
cleated muscle cell (Knudsen, 1992; Yagami-Hiromasa et
al., 1995; Barnoy et al., 1996; Gorza and Vitadello, 2000).
Recent work in Drosophila (Rau et al., 2001) and in mam-
mals (Horsley et al., 2001) has identified genes that regulate
initial fusion events that form a myotube distinctly from the
cell fusion that occurs with an existing myotube. These data
suggest that the formation of a large multinucleated muscle
cell involves two stages of fusion. Thus, initially, a subset of
mononucleated muscle cells fuse with each other to form
small nascent myotubes containing several nuclei. Subse-
quently, additional differentiated muscle cells fuse with the
nascent myotube and muscle growth occurs. In this paper,
we show that PGF2  does not act on the initial fusion of
muscle cells that forms myotubes because PGF2  does not
affect the percentage of nuclei in myotubes (Fig. 1 D);
rather, PGF2  is a novel regulator of the second stage of
muscle cell fusion as it increases the number of nuclei within
myotubes (Fig. 1, E and F). Treatment of muscle cells after
the formation of myotubes has begun is sufficient to induce
this increase in myonuclear number (Fig. 1 G). Thus, in
contrast to other molecules, PGF2  mediates muscle cell
Figure 5. PGF2  does not induce myotube growth or fusion of 
NFATC2
 /  muscle cells. (A) NFATC2
 /  myoblasts were induced 
to differentiate and treated with vehicle or 10
 6 M PGF2  for 48 h, 
followed by immunostaining for EMyHC. Bar, 60  m. (B) Nuclear 
number assays were performed as in Fig. 1 E on NFATC2
 /  cultures 
treated with vehicle or PGF2  at a range of doses. Data are the 
mean   SEM of three independent cell isolates. (C) FP receptor 
mRNA expression was examined by RT-PCR after 24 h in DM in 
wild-type and NFATC2
 /  muscle cells. Representative ethidium 
bromide staining of acrylamide gel is shown with 18S rRNA as an 
internal control.
Figure 6. PGF2  induces hypertrophy of NFATC2
 /  myotubes 
expressing recombinant NFATC2. (A) Primary NFATC2
 /  myoblasts 
were infected either with control (Cntl RV) or recombinant NFATC2 
retrovirus (NFATC2 RV). Cells were induced to differentiate and 
treated with vehicle or 10
 6 M PGF2 . After 48 h, the cells were 
immunostained for EMyHC. Bar, 60  m. (B) Nuclear number assays 
were performed as in Fig. 1 E. Data are the mean   SEM of three 
independent experiments. *Significantly different from vehicle-treated 
cells infected with Cntl RV, P   0.05; **Significantly different from 
vehicle treated cells infected with NFATC2 RV, P   0.05.T
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growth by enhancing myonuclear accretion in the nascent
myotube. Because myoblast fusion requires multiple steps
(Wakelam, 1985), PGF2  could enhance myonuclear accre-
tion by effecting cell motility, alignment, recognition, adhe-
sion, or membrane union.
PGs are a large family of molecules and only a few specific
PGs have been studied in myogenesis. Previously, the effect
of PGF2  on muscle cell fusion was examined with doses of
PGF2  higher than 10
 6 M (Rossi et al., 1989). No effect
was seen with these doses, which is consistent with our re-
sults in Fig. 1 E. Other PGs have been shown to regulate
muscle cell fusion. PGE2 and PGE1 regulate fusion by inhib-
iting and increasing the initial fusion of myoblasts, respec-
tively (Zalin, 1977; Entwistle et al., 1986; Rossi et al.,
1989). Consistent with a general role for PGs in muscle cell
fusion and growth, inhibition of PG synthesis with inhibi-
tors of the cyclooxygenase enzymes inhibits myoblast fusion
(Zalin, 1977; David and Higginbotham, 1981; Entwistle et
al., 1986) and the growth of myofibers in vivo (Templeton
et al., 1986; McLennan, 1987). Given the differential effect
of individual PG molecules on skeletal muscle cells, the syn-
thesis of PG molecules is likely coordinated to control multi-
ple steps of muscle growth.
What is the signal transduction pathway by which PGF2 
induces muscle growth? Our data are consistent with a role
for the PGF2  receptor, FP. Treatment of cells with flupros-
tenol, a specific FP receptor agonist, can activate increases in
myotube size and nuclear number, similar to PGF2  (Fig. 2).
Muscle growth is inhibited by AL-8810, a specific FP recep-
tor antagonist. In addition, the FP receptor is expressed in
skeletal muscle cells at the time of growth and fusion (Fig. 5
C). Several lines of evidence indicate that downstream of FP
receptor activation a calcineurin/NFAT-dependent pathway
is the key requirement for PGF2-induced muscle growth. Ex-
pression of a specific inhibitor of NFAT activation by cal-
cineurin completely abrogates the effects of PGF2  on cell
growth. In addition, PGF2  induces nuclear translocation of
NFATC2 in a calcineurin and FP receptor-dependent man-
ner. Furthermore, increased cell size or myonuclear number
does not occur in response to PGF2  in NFATC2
 /  cells,
but is restored when recombinant NFATC2 is introduced
into the cells. Indirectly, the time in myogenesis in which
PGF2  is effective also supports a role for the involvement of
NFAT. The timing of PGF2  action on myotube growth
(Fig. 1 G) concurs with the timing of NFATC2 activation in
skeletal muscle cells (Abbott et al., 1998), and is consistent
with a role for NFATC2 during the second stage of cell
fusion during myotube growth (Horsley et al., 2001).
Together, these data strongly support a requirement for
NFATC2 in PGF2 -induced skeletal muscle growth, and im-
plicate a calcium signaling pathway downstream of PGF2  in
skeletal muscle growth. The mechanism by which NFATC2
regulates muscle growth is unknown. Few NFAT-regulated
genes are known in cell types outside of the immune system
(Horsley and Pavlath, 2002). The identification of the genes
regulated by the PGF2 -NFATC2 signaling pathway in skele-
tal muscle may reveal novel mechanisms of muscle growth.
Activity is a potent stimulus for muscle growth. Such
muscle stimulation leads to release of PGF2  (Vandenburgh
et al., 1995; Trappe et al., 2001) as well as activation of tran-
scription factors such as NFAT (Liu et al., 2001; Kubis et
al., 2002). The PGF2 -NFATC2 pathway described here
may contribute to regulating muscle growth in vivo. PGF2 
stimulation of cells overexpressing recombinant NFATC2
leads to enhanced cell fusion, and dramatic increases in cell
size or hypertrophy (Fig. 6). PGF2  can induce hypertrophy
of other muscle cell types. Hypertrophic growth of cardiac
myocytes in vitro is stimulated by PGF2  (Adams et al.,
1996; Lai et al., 1996; Kunapuli et al., 1998). In addition,
exogenous PGF2  can stimulate vascular smooth muscle hy-
pertrophy (Dorn et al., 1992). Because cardiac and smooth
muscle are mononucleated cells, hypertrophy of these cell
types does not require cell fusion but involves protein accu-
mulation and thus differs from hypertrophy of skeletal mus-
cle cells, which involves both cell fusion and increased pro-
tein accumulation. Other studies have demonstrated that
PGF2  does increase protein synthesis in skeletal muscle cells
(Vandenburgh et al., 1990). By activating both cell fusion
and protein synthesis, PGF2  may regulate hypertrophy of
skeletal muscle in vivo.
The function of the PGF2 -NFATC2 pathway in skeletal
muscle may be clinically relevant. Nonsteroidal antiinflam-
matory drugs such as celebrex and ibuprofen are a wide-
spread treatment for inflammation and pain relief. Often
these drugs are prescribed after surgery or muscle injury. As
these drugs are inhibitors of cyclooxygenase enzyme activity,
PG synthesis may be decreased and lead to deleterious effects
in skeletal muscle (Mishra et al., 1995), as recently shown
for bone (Simon et al., 2002; Zhang et al., 2002). Our data
suggest that by blocking the production of PGF2  in skeletal
muscle, muscle growth and repair may be impaired in pa-
tients taking nonsteroidal antiinflammatory drugs after mus-
cle atrophy, disease, or injury.
Materials and methods
Cell culture
Primary myoblast cultures were prepared from tibalis anterior muscles of
three adult wild-type and three NFATC2
 /  Balb/c mice (Horsley et al., 2001)
and purified to  99% as described previously (Rando and Blau, 1994; Pav-
lath et al., 1998). Growth media consisted of Ham’s F10, 20% FBS, 5 ng/ml
bFGF, 100 U/ml penicillin G, and 100  g/ml streptomycin. Differentiation
was induced by plating cells on E-C-L (Upstate Biotechnology)–coated
dishes and switching the media to a low serum DM in DME with either 2%
horse serum or insulin-transferrin-selenium-A supplement (GIBCO BRL).
Plasmid production, retroviral infection, and
transient transfections
The GFP-VIVIT and NFATC2 retroviral constructs have been described
previously (Friday et al., 2000; Horsley et al., 2001). An NFATC2-GFP
construct was created by PCR amplification of NFATC2 cDNA from the
vector pREP4-NFATC2 to generate a 2.8-kb product (Ranger et al., 2000).
The forward primer consisted of an EcoRI site followed by bases 224–241
of the human NFATC2 mRNA (GenBank/EMBL/DDBJ accession no.
U43342), whereas the reverse primer contained a XmaI site and bases
2978–2995, which deleted the native stop codon of NFATC2. The ampli-
fied NFATC2 cDNA was then cloned into pEGFP-N1 (CLONTECH Labora-
tories, Inc.), preceding the EGFP coding sequence. An NFAT- MHC en-
hancer-luciferase construct containing the minimal  -MHC promoter
linked to nine copies of a consensus NFAT binding site without an associ-
ated AP-1 site was a gift from J. Molkentin (Children’s Hospital Medical
Center, Cincinnati, OH).
Production of infectious retrovirus and infection of primary myoblasts
were performed as described previously (Abbott et al., 1998). Cells were
subject to two rounds of infection with an efficiency of gene transfer of
 90% based on visualization of green fluorescent protein. Experiments us-T
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ing the NFATC2 retrovirus were begun 48 h after the final infection when
maximum levels of gene expression were achieved. In contrast, experi-
ments using VIVIT retrovirus were begun 24 h after the final infection, be-
fore maximum levels of gene expression in order for normal myotube for-
mation to occur.
For transient transfections, myoblasts were plated in 6-well dishes at
2.5   10
5 cells/well. For each well, 4  g DNA was complexed with 6  l
Lipofectamine 2000 (Promega) for 20 min at room temperature in a total
volume of 500  l in Ham’s F10. The DNA–Lipofectamine mixture was
added to wells containing 2 ml Ham’s F10 and incubated for 4 h at 37 C
after which the cells were re-fed with fresh growth media.
Drug treatment
Primary myoblasts were plated at 2   10
5 cells per well of 6-well dishes.
After 2 h, cells were placed in DM with either vehicle (0.095% ethanol),
PGF2  (Sigma-Aldrich), 17-phPGF2  (Cayman Chemical), or fluprostenol
(BIOMOL Research Laboratories, Inc.), and drugs were replenished at 24 h
unless otherwise noted. Cells were treated with AL-8810 (Sigma-Aldrich)
after 24 h in DM. Doses were chosen and used in the range where maxi-
mal effects were shown in a variety of assays using cardiac (Adams et al.,
1996; Kunapuli et al., 1998; Yew et al., 1998) and smooth muscle cells
(Griffin et al., 1998; Katsuyama et al., 2002).
Differentiation and fusion assays
After 24 or 48 h in DM, cells were fixed in either ice-cold methanol or
3.7% formaldehyde for 10 min and nonspecific binding was blocked with
TNB buffer (NEN Life Science Products) for 1 h at room temperature. The
cells were incubated with an antibody against EMyHC (F1.652, neat hy-
bridoma supernatant; Developmental Studies Hybridoma Bank) for 1 h at
room temperature. Cells were washed in PBS with 0.1% Tween, and then
incubated in biotinylated goat anti–mouse IgG (1:200; Jackson ImmunoRe-
search Laboratories). Antibody binding was detected using Vectastain Elite
ABC reagent (Vector Laboratories) and diaminobenzidine.
To analyze differentiation, the number of nuclei in EMyHC-positive
cells was counted and expressed as a percentage of the total number of nu-
clei analyzed (250). The fusion index was determined by dividing the
number of nuclei within myotubes (two or more nuclei) by the total num-
ber of nuclei analyzed (100–250). Fusion was also analyzed by performing
nuclear number assays. The number of nuclei within individual myotubes
was counted for 50–100 myotubes. Myotubes were grouped into two cate-
gories: those with two to four nuclei and those with five or more nuclei.
The percentage of myotubes in each category was calculated.
DNA quantification
The DNA content of whole cell lysates was quantified after 48 h in DM for
vehicle and PGF2 -treated cells. Cells were washed twice in ice-cold PBS,
scraped off of the dish, and collected by centrifugation at 10,000 g at 4 C.
Cell lysates were resuspended in 250  l of saline phosphate buffer (0.05 M
NaPO4, and 2 M NaCl, pH 7.4) and frozen. Samples were thawed and son-
icated for 15 s, and a 50- l aliquot of each sample was added to the buffer
containing 0.5  g/ml Hoechst 33258 (Molecular Probes). DNA concentra-
tion was determined by measuring the emission at 465 nm after excitation
at 365 nm (Labarca and Paigen, 1980) using an Amicon-Bowman lumines-
cence spectrophotometer (Spectronic Instruments). Calf thymus DNA was
used to construct the standard curve.
FP receptor RT-PCR
RNA was isolated from wild-type and NFATC2
 /  muscle cells after 24 h
in DM using TRIzol reagent (Life Technologies). RT-PCR was performed for
each sample using specific primers for the murine FP receptor (GenBank/
EMBL/DDBJ accession no. D17433): sense, 5 -CACAACCTGCCAGAC-
GAGAACC-3 ; antisense, 5 -ATGGGCAGCACAGCCACGAAC-3 ; 452
base pair. 18S rRNA was used as an internal control in each sample using
QuantumRNA 18S primers (Ambion). The amplification cycle for the FP
receptor consisted of 94 C for 5 min, followed by 35 cycles of 94 C for
30 s, 61.5 C for 30 s, 72 C for 45 s, and termination at 72 C for 5 min. The
amplification cycle for the 18S rRNA consisted of 94 C for 5 min, followed
by 30 cycles of 94 C for 30 s, 57 C for 30 s, 72 C for 30 s, and termination
at 72 C for 5 min. The products were resolved by electrophoresis on a
1.5% agarose gel and visualized by ethidium bromide staining.
NFATC2 nuclear translocation
24 h after transient transfection, cells were plated at 2   10
5 cells per well
of ECL-coated 6-well plates, and switched to DM after 2 h. After 24 h in
DM, cells were placed in DME for 3 h, treated with 10
 6 M PGF2  alone or
in combination with 10
 6 M CsA or 10
 6 M AL-8810 for 30 min, and fixed
with 3.7% formaldehyde.
Reporter assays
24 h after transient transfection with an NFAT reporter construct, myo-
blasts were plated at 7.5   10
4 cells per well of ECL-coated 24-well plate.
The medium was replaced with DME and the cells were allowed to differ-
entiate for 24 h. Cells were stimulated with 10
 6 M PGF2  alone or in com-
bination with 10
 6 M CsA for 5 h and assayed for luciferase as described
previously (Abbott et al., 1998).
Statistics
To determine significance between two groups, comparisons were made
using t tests. Analyses of multiple groups were performed using one-way
ANOVA with Bonferroni’s post test using GraphPad Prism version 3.0a for
Macintosh (GraphPad Software). For all statistical tests, the 0.05 level of
confidence was accepted for statistical significance.
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